miRNA nanotherapeutics: potential and challenges in respiratory disorders

References

• 1. Wisnivesky J, de-Torres JP. The global burden of pulmonary diseases: most prevalent problems and opportunities for improvement. Ann. Glob. Health 85(1), 1–2 (2019).
  MedlineGoogle Scholar
• 2. Dua K, Chellappan DK, Singhvi G, de Jesus Andreoli Pinto T, Gupta G, Hansbro PM. Targeting microRNAs using nanotechnology in pulmonary diseases. Panminerva Med. 60(4), 230–231 (2018).
  MedlineGoogle Scholar
• 3. Wadhwa R, Aggarwal T, Malyla V et al. Identification of biomarkers and genetic approaches toward chronic obstructive pulmonary disease. J. Cell. Physiol. 234(10), 16703–16723 (2019).
  Medline CASGoogle Scholar
• 4. Maltby S, Plank M, Tay HL, Collison A, Foster PS. Targeting microRNA function in respiratory diseases: mini-review. Front. Physiol. 7, 21 (2016).
  MedlineGoogle Scholar
• 5. Weinstein S, Peer D. RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology 21(23), 232001 (2010).
  MedlineGoogle Scholar
• 6. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23(4), 457–462 (2005).
  Medline CASGoogle Scholar
• 7. Awasthi R, Rathbone MJ, Hansbro PM, Bebawy M, Dua K. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology. Drug Deliv. Transl. Res. 8(1), 97–110 (2018).
  Medline CASGoogle Scholar
• 8. Dua K, Hansbro NG, Foster PS, Hansbro PM. MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases. Drug Deliv. Transl. Res. 7(1), 168–178 (2017).
  Medline CASGoogle Scholar
• 9. McCully M, Conde J, VB P, Mullin M, Dalby MJ, Berry CC. Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells. PLoS ONE 13(2), e0192562 (2018).
  MedlineGoogle Scholar
• 10. Sharma A, Kumar M, Ahmad T et al. Antagonism of mmu-mir-106a attenuates asthma features in allergic murine model. J. Appl. Physiol. 113(3), 459–464 (2012).
  Medline CASGoogle Scholar
• 11. Dua K, Rapalli VK, Shukla SD et al. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: emerging need for novel drug delivery approaches. Biomed. Pharmacother. 107, 1218–1229 (2018).
  Medline CASGoogle Scholar
• 12. Riley MK, Vermerris W. Recent advances in nanomaterials for gene delivery – a review. Nanomaterials (Basel) 7(5), doi:10.3390/nano7050094 (2017).
  MedlineGoogle Scholar
• 13. Davies OR, Head L, Armitage D et al. Surface modification of microspheres with steric stabilizing and cationic polymers for gene delivery. Langmuir 24(14), 7138–7146 (2008).
  Medline CASGoogle Scholar
• 14. Mohamed A, Kunda NK, Ross K, Hutcheon GA, Saleem IY. Polymeric nanoparticles for the delivery of miRNA to treat chronic obstructive pulmonary disease (COPD). Eur. J. Pharm. Biopharm. 136, 1–8 (2019).
  Medline CASGoogle Scholar
• 15. Moro M, Di Paolo D, Milione M et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J. Control. Release 308, 44–56 (2019).
  Medline CASGoogle Scholar
• 16. McKiernan PJ, Cunningham O, Greene CM, Cryan SA. Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology. Int. J. Nanomedicine 8, 3907–3915 (2013).
  MedlineGoogle Scholar
• 17. Kasinski AL, Kelnar K, Stahlhut C et al. A combinatorial microRNA therapeutics approach to suppressing non-small-cell lung cancer. Oncogene 34(27), 3547–3555 (2015).
  Medline CASGoogle Scholar
• 18. Trang P, Wiggins JF, Daige CL et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19(6), 1116–1122 (2011).
  Medline CASGoogle Scholar
• 19. Shi S, Han L, Deng L et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J. Control. Release 194, 228–237 (2014).
  Medline CASGoogle Scholar
• 20. Song Y, Zhou B, Du X et al. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small-cell lung cancer (NSCLC). Biomed. Pharmacother. 125, 109561 (2020).
  Medline CASGoogle Scholar